【文档说明】替格瑞洛Champion-Phoenix-III期临床试验结果系列课件.ppt，共(39)页，4.506 MB，由小橙橙上传

转载请保留链接：https://www.ichengzhen.cn/view-253356.html

以下为本文档部分文字说明：

CHAMPIONPHOENIXDeepakL.Bhatt,MD,MPH,GreggW.Stone,MD,KennethW.Mahaffey,MD,C.MichaelGibson,MS,MD,Ph.GabrielSteg,MD,Chris

tianHamm,MD,MatthewPrice,MD,SergioLeonardi,MD,DianneGallup,MS,MeredithTodd,SimonaSkerjanec,PharmD,HarveyD.White,DSc,andRobertA.Harrin

gton,MD,onbehalfoftheCHAMPIONPHOENIXInvestigatorsDr.Bhatt–AdvisoryBoard:MedscapeCardiology;BoardofDirect

ors:BostonVAResearchInstitute,SocietyofChestPainCenters;Chair:AmericanHeartAssociationGetWithTheGuidelinesScienceSubcommittee;Honoraria:Amer

icanCollegeofCardiology(Editor,ClinicalTrials,Cardiosource),DukeClinicalResearchInstitute(clinicaltrialsteeringcommittees),SlackPublications(Chief

MedicalEditor,CardiologyTodayIntervention),WebMD(CMEsteeringcommittees);Other:SeniorAssociateEditor,Journa

lofInvasiveCardiology;ResearchGrants:Amarin,AstraZeneca,Bristol-MyersSquibb,Eisai,Ethicon,Medtronic,SanofiAve

ntis,TheMedicinesCompany;UnfundedResearch:FlowCo,PLxPharma,Takeda.Thispresentationincludesoff-labeland/orin

vestigationalusesofdrugs,includingclopidogrelandcangrelor.TheCHAMPIONPHOENIXtrialwasfundedbyTheMedicinesCompany.Disclos

uresAntiplateletTherapy►AntiplatelettherapyisacriticalpartofcontemporaryPCI.►Intheeraofaspirinandunfractionatedheparin,intravenousglycoprotei

nIIb/IIIainhibitionsignificantlyreducedimportantperiproceduralischemicevents,butsignificantlyincreasedbleeding.►ADPreceptorantagonismwithoralagen

tswasalsoshowntoreduceischemiceventsinPCIandespeciallyACS.►However,availableoralagentsarelimitedbytheirrelativelylongdurationofactionandbioava

ilability,whichmightbealiability:▪ifgivenpriortocoronaryangiographyandurgentoremergentCABGisdeemedneces

sary,▪insituationswhereabsorptionmaybeproblematic,suchaswithrapidtimestoPCI,▪inpatientswhoareintubated,nauseated,withSTEMI,orshock.Harrington

RA,etal.PURSUIT.NEJM1998DesaiNandBhattDL.PeriproceduralAntiplateletTherapy.JACCIntervention2010Cangrelor►Cangrelorisanintr

avenousADPreceptorantagonistthatisrapidlyacting,potent,andreversible,withreturnofnormalplateletfunctionwithinanhour.►Cangrelorwa

sstudiedpreviouslyintwolargePhase3PCItrials,CHAMPIONPCIandCHAMPIONPLATFORM.Neitherstudymetitsprimaryendpoint,butthesecondaryendpointofstentthro

mbosisat48hourswassignificantlyreducedinCHAMPIONPLATFORMandinaprespecifiedpooledanalysisofthetwotrials.Therewasnoexcessinseverebleeding.►Thepotential

efficacysignalpromptedustolaunchtheCHAMPIONPHOENIXtrial.HarringtonRA,etal.CHAMPIONPCI.NEJM2009BhattDL,etal.CHAMPIONPLATFORM.NEJM2009WhiteHD,etal

.Meta-AnalysisofCHAMPIONPCIandPLATFORM.AHJ2012CHAMPIONPHOENIXExecutiveCommitteeDeepakL.Bhatt,M.D.,M.P.H.(Co-PrincipalInvestigator)VABostonH

ealthcareSystem,BrighamandWomen'sHospital,andHarvardMedicalSchoolBoston,MARobertA.Harrington,M.D.(Co-Principal

Investigator)DepartmentofMedicine,StanfordUniversity,Stanford,CAC.MichaelGibson,M.S.,M.D.BethIsraelDeaconessMedica

lCenter,DivisionofCardiology,Boston,MAChristianW.Hamm,M.D.KerckhoffHeartandThoraxCenter,BadNauheim,GermanyKennethW.Mahaffey,M.D.DukeClinicalRese

archInstitute,Durham,NCMatthewJ.Price,M.D.ScrippsClinicandScrippsTranslationalScienceInstitute,LaJol

la,CAPh.GabrielSteg,M.D.INSERMU-698,UniversitéParis-Diderot,andHôpitalBichat,Assistance-Publique-HôpitauxdePa

ris,Paris,FranceGreggW.Stone,M.D.ColumbiaUniversityMedicalCenterandtheCardiovascularResearchFoundation,NewYork,NYHarveyD.

White,D.Sc.AucklandCityHospital,Auckland,NewZealandCHAMPIONPHOENIXDSMBFransVandeWerf,M.D.(Chair)Universitai

rZiekenhuisGasthuisberg,BelgiumDavidP.Faxon,M.D.Brigham&Women’sHospital,Dept.ofMedicine,Boston,MAE.Ma

gnusOhman,M.D.DukeUniversityMedicalCenter,Durham,NCFreekW.A.Verheugt,M.D.HeartcenterUniversityMedicalCenter,Am

sterdamW.DouglasWeaver,M.D.HenryFordHospital,Detroit,MIJanG.P.Tijssen,Ph.D.(Statistician)DepartmentofCardiology,AcademicMed

icalCenter-UniversityofAmsterdam,TheNetherlandsCHAMPIONPHOENIXCECDukeClinicalResearchInstituteREVIEWERSPhase1LucianaAmaganijanBrazilMonique

AndersonNCAkshayBagaiNCRobertW.HarrisonNCPedroG.MelodeBarrosESilvaBrazilPhase2J.MatthewBrennanNCRenatoD.LopesNCChiaraMelloniN

CPierluigiTricociNCLEADERSHIPKennethW.Mahaffey(Chair)SergioLeonardi(co-Chair)DianneGallup(LeadStatistician)MatthewD.Wilso

n(ProjectLeader)OPERATIONSStaceyMangum(Coordinator)LindaDowd(LeadCDA)DimitriosStournaras(LeadCDS)SachinVyas(

LeadCTA)CHAMPIONPHOENIXAngiographicCoreLabCardiovascularResearchFoundationMariaAlfonsoAntoinetteAllenGerardCondittRo

saDeJesusChampikaDjurkovicSharwatJahanGregKaluzaElenaKonovalovaMitchellLustreKatharineLymberisDuvalMichelSofiaPapamitrouNicolettaPavloviciKharyP

errySairaPunjwaniConnieQiuRaquelSanchezEliasSanidasShawnaleeVassellDoueyWrightReviewersandDataEntryStaffLeadershipPhilippeGénéreux(Director)Sorin

BrenerLauraLasalle12Countries│153SitesUSAPolandGermanyAustriaThailandRussiaGeorgiaBulgariaBrazilCzechRepublicUSAPolandGermanyNewZealandAustriaI

talyThailandRussiaGeorgiaBulgariaBrazilCHAMPIONPHOENIX–AGlobalTrialCHAMPIONPHOENIXStudyDesign►Randomized,double-blind,

double-dummy,superiority►Primaryefficacyendpoint:Death/MI/IDR/STat48hours▪Adjustedfor600mgversus300mgclopidogreluse▪ModifiedIntent-to-Treat

(MITT)analysis(patientsactuallygotstudydrugandPCI)►Keysecondaryendpoint:StentThrombosisat48hours►Efficacyendpointsalsoexaminedat30days►Primarysaf

etyendpoint:GUSTOSevereBleedingat48hoursHarringtonRA,etal.CHAMPIONPCI.NEJM2009BhattDL,etal.CHAMPIONPLATFORM.N

EJM2009WhiteHD,etal.Meta-AnalysisofCHAMPIONPCIandPLATFORM.AHJ2012CHAMPIONPHOENIXStudyDesign12to4hours0Cangrelor2bolus&infusion(30ug/kg

;4ug/kg/min)Clopidogrel600mgoralCHAMPIONPHOENIXN=10,900MITTSA/NSTE-ACS/STEMIPatientsrequiringPCI1P2Y12inhibitornaïveORPlacebo3oral

(rightbeforePCIorrightafter,perphysician)Placebo2bolus&infusionPlacebooralPCI~30’ORClopidogrel3(600m

gor300mgoral,perphysician)1RandomizationoccurredoncesuitabilityforPCIwasconfirmedeitherbyangiographyorSTEM

Idiagnosis.Doubleblindstudymedicationwasadministeredassoonaspossiblefollowingrandomization.2StudydrugInfusion(cangrelorormatchingplacebo)wascontinue

dfor2-4hoursatthediscretionofthetreatingphysician.Attheendoftheinfusionpatientsreceivedaloadingdoseofclopidogrelormatchingpla

ceboandweretransitionedtomaintenanceclopidogreltherapy.3Clopidogrelloadingdose(ormatchingplacebo)wasadmi

nisteredasdirectedbytheinvestigator.Atthetimeofpatientrandomization,aclopidogrelloadingdoseof600mgor300mgwasspecifiedbytheinvestigat

or.MITT=modifiedintent-to-treat;NSTE-ACS=non-ST-elevationacutecoronarysyndrome;PCI=percutaneouscoronaryinter

vention;SA=stableangina;STEMI=ST-elevationMI.RandDemographics,MITTCangrelor(N=5472)Clopidogrel(N=5470)Age,year

s6464Female28%27%Diabetesmellitus28%28%PatientTypeStableangina57%55%NSTE-ACS25%26%STEMI18%19%LoadingDose300mgclopidogrel26%26%600mgclopidogrel74%7

4%RegionUnitedStates37%37%Othercountries63%63%PrimaryEfficacyOutcomesat48Hours,MITTCangrelor(N=5472)Clopidogrel(N=5470)

OR(95%CI)P-valuePrimaryAnalysisAdjusted1Death/MI/IDR/ST257/5470(4.7%)322/5469(5.9%)0.78(0.66,0.93)0.0051.Thelogisticmodelwasadjus

tedforbaselinestatusandclopidogreldose.Pvalueof0.006shownontheKMcurveislogrankpvalue.SecondaryEfficacyOutcomesat48Hours,MITTStentthrombosis(keyse

condaryendpoint)46/5470(0.8%)74/5469(1.4%)0.62(0.43,0.90)0.01MI207/5470(3.8)255/5469(4.7)0.80(0.67,0.97)0.02Q-waveMI11/5470(0.2)18/54

69(0.3)0.61(0.29,1.29)0.19IDR28/5470(0.5)38/5469(0.7)0.74(0.45,1.20)0.22Death18/5470(0.3)18/5469(0.3)1.00(0.52,1.92)>0.99CVDeath18/5470(0.

3)18/5469(0.3)1.00(0.52,1.92)>0.99BhattDL,StoneGW,MahaffeyKW,etal….HarringtonRA.NEJM2013atwww.nejm.orgDeath/MI/IDR/StentThro

mbosiswithin48HoursPatientatRiskHoursfromRandomizationCangrelor:547252335229522552235221522052175213Clopidogrel

:547051625159515551525151515151475147cangrelorclopidogrel5.9%4.7%LogRankPValue=0.006EventRate(%)BhattDL,StoneGW,MahaffeyKW,etal

….HarringtonRA.NEJM2013atwww.nejm.orgcangrelorclopidogrelLogRankPValue=0.01PatientatRiskHoursfromRandomizationCan

grelor:547254265421541954195418541754165414Clopidogrel:5470539253895388538653855385538353831.4%0.8%EventRate(%)StentThrombosiswithin48HoursBhattD

L,StoneGW,MahaffeyKW,etal….HarringtonRA.NEJM2013atwww.nejm.orgEfficacyOutcomesat30Days,MITTCangrelor(N=5472)Clopidogrel(N=5470)O

R(95%CI)PValueDeath/MI/IDR/ST(primaryendpoint,adjusted)326/5462(6.0%)380/5457(7.0%)0.85(0.73,0.99)0.03Stentthrombosis71/5462(1.

3%)104/5457(1.9%)0.68(0.50,0.92)0.01MI225/5462(4.1%)272/5457(5.0%)0.82(0.68,0.98)0.03Q-waveMI14/5462

(0.3%)22/5457(0.4%)0.63(0.32,1.24)0.18IDR56/5462(1.0%)66/5457(1.2%)0.85(0.59,1.21)0.36Death60/5462(1.1%)55/5457(1.0%)1.09(0.76,1.58)0.

64CVDeath48/5462(0.9%)46/5457(0.8%)1.04(0.69,1.57)0.84BhattDL,StoneGW,MahaffeyKW,etal….HarringtonRA.NEJM2013atwww.nejm.orgOR[95%CI]P[Int]Over

all0.79(0.67,0.93)Age≥750.71(0.50,1.02)0.55Age<750.81(0.67,0.98)Male0.84(0.69,1.03)0.23Female0.67(0.50,0.92)Ethnicity:White0.80(0.67,0.95

)0.72Ethnicity:Non-white0.70(0.35,1.41)UnitedStates0.70(0.53,0.92)0.26OtherCountries0.85(0.69,1.05)StableAngina0.78(0.63,0.95)0.

98NSTE-ACS0.80(0.55,1.17)STEMI0.75(0.46,1.25)Weight>=600.79(0.66,0.94)0.89Weight<600.75(0.39,1.45)BiomarkerPositive0.90(0.64,1.27)0.3

5BiomarkerNegative0.75(0.61,0.91)DiabeticNo0.74(0.61,0.90)0.26DiabeticYes0.92(0.67,1.27)Insulin-Depe

ndentDiabetes:Yes0.74(0.42,1.31)0.82Insulin-DependentDiabetes:No0.79(0.66,0.94)PriorMI0.68(0.47,0.97)0.30NoPriorMI0.84(0

.69,1.02)5.01.00.2Subgroups:Death/MI/IDR/STat48HoursCangrelorBetterClopidogrelBetterOR[95%CI]P[Int]PriorTIA/Stroke0.78(0.37,1.63

)0.97NoPriorTIA/Stroke0.79(0.66,0.94)HistoryofPAD0.36(0.21,0.63)0.003NoHistoryofPAD0.86(0.72,1.03)HistoryofCHF0.73(0

.45,1.20)0.74NoHistoryofCHF0.80(0.67,0.96)Clopidogrel300mg0.84(0.62,1.14)0.62Clopidogrel600mg0.77(0.63,0.94)Bivalirudinonly0.69(0.47,1.01)0.51Heparin

only0.80(0.65,0.98)Femoral0.79(0.65,0.96)0.83Radial0.76(0.54,1.06)#vessels=10.80(0.66,0.97)0.51#vessels≥20.70(0.49,0.99)Drug-ElutingStent0.8

0(0.64,1.01)0.79Bare-MetalStent0.77(0.60,0.99)Aspirin≤100mg0.80(0.63,1.00)0.49Aspirin>100mg0.70(0.52,0.94)ClopidogrelLoadbeforePCIStart0

.80(0.64,0.98)0.99ClopidogrelLoadafterPCIStart0.79(0.59,1.06)Cangrelorinfusion≤129minutes0.85(0.68,1.07)0.31Cangrelorinfusion>129minu

tes0.72(0.56,0.92)Subgroups:Death/MI/IDR/STat48Hours(continued)5.01.00.2CangrelorBetterClopidogrelBetterNon-CABGBleedingat4

8Hours,SafetyBleedingScaleCangrelor(N=5529)Clopidogrel(N=5527)OR(95%CI)PValueGUSTOSevere9(0.16%)6(0.11%)1.50(0.53

,4.22)0.44GUSTOModerate22(0.4%)13(0.2%)1.69(0.85,3.37)0.13GUSTOSevere+Moderate31(0.6%)19(0.3%)1.63(0.92,2.90)0.09TIMIMajor5(0

.1%)5(0.1%)1.00(0.29,3.45)>0.999TIMIMinor9(0.2%)3(0.1%)3.00(0.81,11.10)0.08TIMIMajor+Minor14(0.3%)8(0.1%)1.75(0.73,4.18)0.2Any

BloodTransfusion25(0.5%)16(0.3%)1.56(0.83,2.93)0.16ACUITYMajor235(4.3%)139(2.5%)1.72(1.39,2.13)<0.001ACUITYw/outhem

atoma42(0.8%)26(0.5%)1.62(0.99,2.64)0.05BhattDL,StoneGW,MahaffeyKW,etal….HarringtonRA.NEJM2013atwww.nejm.orgOR[95%CI]P[Int]O

verall1.63(0.92,2.90)Age≥751.07(0.45,2.53)0.21Age<752.24(1.02,4.93)Male0.93(0.41,2.12)0.07Female2.75(1.16,6.5

1)Ethnicity:White1.86(0.97,3.56)0.40Ethnicity:Non-white1.02(0.29,3.56)UnitedStates1.34(0.56,3.18)0.55OtherCountries1.90(0.88,4.10)StableAngin

a1.45(0.59,3.56)0.93NSTE-ACS1.79(0.52,6.13)STEMI1.84(0.72,4.70)Weight>=601.52(0.80,2.86)0.71Weight<602.01(0.52,7.86)BiomarkerPos

itive1.51(0.64,3.53)0.79BiomarkerNegative1.76(0.81,3.82)DiabeticNo1.90(0.88,4.09)0.56DiabeticYes1.35(0.57,3.20)Insulin-Depende

ntDiabetes:Yes3.56(0.40,32.00)0.45Insulin-DependentDiabetes:No1.52(0.83,2.76)PriorMI3.25(0.65,16.12)0.35NoPriorMI1.44(0.78,2.67)Cl

opidogrelBetterSubgroups:GUSTOSevere/ModerateBleeding,Safety5.01.00.2CangrelorBetterSubgroups:GUSTOSevere/ModerateBleeding,Safety(continue

d)ClopidogrelBetter5.01.00.2CangrelorBetterOR[95%CI]P[Int]PriorTIA/Stroke0.92(0.13,6.55)0.54NoPriorTIA/Stroke1.72(0.9

4,3.13)HistoryofPADNA0.10NoHistoryofPAD1.55(0.84,2.87)HistoryofCHF2.13(0.39,11.70)0.85NoHistoryofCHF1.79(0.95,3.37)Clopidogrel3

00mg4.02(1.13,14.27)0.09Clopidogrel600mg1.19(0.61,2.31)Bivalirudinonly0.86(0.26,2.83)0.26Heparinonly1.89(0.91,3.93)Femoral

1.68(0.90,3.11)0.81Radial1.37(0.31,6.11)#vessels=11.81(0.94,3.49)0.48#vessels≥21.12(0.34,3.68)Drug-ElutingStent1.26(

0.57,2.77)0.35Bare-MetalStent2.17(0.93,5.03)Aspirin≤100mg1.58(0.52,4.85)0.93Aspirin>100mg1.49(0.74,3.03)ClopidogrelLoad

beforePCIStart1.24(0.58,2.66)0.25ClopidogrelLoadafterPCIStart2.53(0.98,6.54)Cangrelorinfusion≤129minutes1.71(0.81,3.59)0.85Cangrelor

infusion>129minutes1.52(0.62,3.73)SummaryofTreatmentEmergentAdverseEventsAdverseEventCangrelor(N=5529)Clopidogrel(N=5527)PValue

PatientswithatleastoneAE20.2%19.1%0.13PatientswithatleastoneAEcausingstudydrugdiscontinuation0.5%0.4%0.21Transientdyspnea1.2%0

.3%<0.001BhattDL,StoneGW,MahaffeyKW,etal….HarringtonRA.NEJM2013atwww.nejm.orgLimitations►Aloadingdoseof60

0mghasbecomemorecommonthan300mg▪However,inthethreequartersofpatientswhoreceived600mg,thebenefitofcangrelorremainedstatistic

allysignificantandwasnotattenuated.►Itispossiblethebenefitswesawherewouldhavebeenattenuatedwithalongerdurationofpretreatment.▪Ofnote,theclop

idogrelpretreatmentwasgiven“onthetable”asisconsistentwithmanypracticesaroundtheworldandinparticularintheUnitedState

s.▪Importantly,prospectiverandomizedclinicaltrials,namelyCREDOandPRAGUE-8,didnotfindasignificantbenefitforclopidogrelpretreatm

ent.►Thebenefitsseenheremayalsohavebeenattenuatedhadprasugrelorticagrelorbeenusedinthecontrolarm.▪However,todate,thelargesttrialofprasugrelpretr

eatment,ACCOAST,wasterminatedbytheDSMBforlackofefficacyandexcessbleeding.▪Thus,oralpretreatment,whilebiologicallyappealingandintuitive,remainsunp

roveninprospectiverandomizedclinicaltrials.Conclusions►InCHAMPIONPHOENIX,intravenousADPreceptorantagonismwithcangrelorsignificantly(p=0.0

05)reducedthecompositeofdeath,myocardialinfarction,ischemia-drivenrevascularization,orstentthrombosisat48hours,witha22%oddsreduc

tion.►Thekeysecondaryendpointofstentthrombosiswasalsosignificantlyreduced,witha38%oddsreduction.►Thebenef

itwassustainedthrough30days.►Therewasnoexcessinseverebleedingortransfusions.►Intravenouscangrelormaybeanattractiveoptionacrossthefull

spectrumofPCI,includingstableangina,NSTEMI,andSTEMI.ForFullDetails,PleaseGotowww.NEJM.orgBhattDL,StoneGW,MahaffeyKW,etal….Harringto

nRA.NEJM2013atwww.nejm.orgTHANKYOU!BACKUPSLIDESCangrelor►DirectplateletP2Y12receptorantagonist►ATPanalogueMW=800Daltons►Parenteraladministration►T

1/2=3to6minutes►Offset=60minutesNNNNNHSCF3OHOHOOPOOPPOOOClClOOOS4Na+AngiolilloDJ,SchneiderDJ,BhattDL,etal.Pharmacodynamiceffectsofc

angrelorandclopidogrel:theplateletfunctionsubstudyfromthecangrelorversusstandardtherapytoachieveoptimalmanagementofplatel

etinhibition(CHAMPION)trials.JThrombThrombolysis2012;34:44-55.CHAMPIONPCI|PLATFORM►PCI|allcomersPCI|58%ACS|onclopido

grelallowed|clopidogrel600mgadministeredatthestartofPCIinthecontrolarm►PLATFORM|allcomersPCI|65%ACS|clop

idogrelnaïve|clopidogrel600mgadministeredattheendofPCIinthecontrolarm12hours0PCI~25’Cangrelor30g/kgthen4g

/kg/minCangrelor30g/kgthen4g/kg/minClopidogrel600mgoralClopidogrel600mgoralCHAMPIONPCIN=9000SA/UA/ACS/STEMIOnclopidog

relallowedCHAMPIONPLATFORMN=6400SA/UA/ACSNoclopidogrelallowedHarringtonRA,etal.NEJM2009BhattDL,etal.NEJM200948-HourEventsPLATFORMOR[95%CI]Pva

lueDeath/MI/IDR0.87(0.71,1.07)0.17Death/Q-MI/IDR0.55(0.33,0.93)0.02Death/Q-MI/ST0.38(0.20,0.72)0.003PCIDeath/MI/IDR1.05(0.89,1.24)0.

57Death/Q-MI/IDR0.66(0.42,1.05)0.08Death/Q-MI/ST0.74(0.43,1.27)0.27POOLEDDeath/MI/IDR0.97(0.86,1.11)0.68D

eath/Q-MI/IDR0.61(0.43,0.86)0.005Death/Q-MI/ST0.55(0.36,0.83)0.004CangrelorBetter5.02.01.00.20.5ComparatorBetterSummaryofClinicalEffica

cy1.BhattDL,LincoffAM,GibsonCM,etal.IntravenousplateletblockadewithcangrelorduringPCI.NEnglJMed2009;361:2330-41.2.Harrin

gtonRA,StoneGW,McNultyS,etal.PlateletinhibitionwithcangrelorinpatientsundergoingPCI.NEnglJMed2009;361:2318-29.3.WhiteHD,Ch

ewDP,DauermanHL,etal.AHJ2012.CHAMPIONPHOENIXLessonsfromCHAMPIONPCI|PLATFORMTrialDesignImplementationPatientpopulationAllcomersPCIIn

clusionofpatientswithnormalcardiacmarkersatbaseline|est.65%trialpopulationP2Y12inhibitornaïvePatientsnotpre-treate

dwithP2Y12inhibitorwithin7dayspriortoangiogramEndpointdefinitionsMIdefinition1UDMI|CentrallabtoassureconsistencyofCKMBmassassayglobally|angio

graphiccorelabtoconsistentlyassessevidenceofischemiaStentthrombosisdefinition2ARCDefinitionincludesoc

currenceassociatedwithIDR|Death|MI|alsointra-proceduralstentthrombosismeasuredbyangiographiccorelab31.Thygesen

K,AlpertJS,andWhiteHD,onbehalfoftheJointESC/ACCF/WHFTaskForcefortheRedefinitionofMyocardialInfarction.Universaldefinitionofmyocardialinfarc

tion.EurHeartJ.2007;28:2525-2538.2.CutlipDE,WindeckerS,MehranR,etal.Clinicalendpointsincoronarystenttrials

:acaseforstandardizeddefinitions.Circulation2007;115:2344-2351.3.BrenerSJ,CristeaE,KirtaneAJ,etal.Intra-ProceduralStentThrombosis.JAmCol

lCardiolIntv2013;6:36–43.UniversalDefinitionofMIThygesenK,AlpertJS,andWhiteHD,onbehalfoftheJointESC/ACCF/WHFTaskForcefo

rtheRedefinitionofMyocardialInfarction.Universaldefinitionofmyocardialinfarction.EurHeartJ.2007;28:2525

-2538.BetterdiscriminationofMIwithconsiderationofmultiplecriteriaCKMBelevations|ischemicsymptoms|angio

graphicevidence|ECGchangesDiagnosisofMIfromvariousperspectivesType1|spontaneousMIrelatedtoischemiaType2|MIsecondar

ytoischemia|changeinO2demand/supplyType3|suddenunexpectedcardiacdeathType4|associatedwithcoronaryangioplasty

|stentsType4a|MIassociatedwithPCIType4b|MIassociatedwithStentThrombosisType5|MIassociatedwithCABGDefinition

ofSTAngiographicEvidence:ARCST(AcademicResearchConsortium)1►Acute(<24hourspost-procedure)►Subacutestentthrombosis(>24hoursand≤30days)▪Definitefromp

robablestentthrombosis▪AdjudicatedbytheCECIPST(Intra-proceduralstentthrombosis)►Neworworseningthrombusrelatedtotheste

ntor►Abruptclosureduetothrombosis1.CutlipDE,WindeckerS,MehranR,etal.Clinicalendpointsincoronarystenttrials:acasefor

standardizeddefinitions.Circulation2007;115(17):2344-2351.SampleSizeEstimation►Eventrateof5.1%intheclopidogrelarmand3.9%inthe

cangrelorarm(24.5%reductioninoddsratio)►N=10,900(powerof85%todetectthisdifferenceattheonesidedsignificancelevelof0.025)BhattDL,StoneGW,Mahaf

feyKW,etal….HarringtonRA.NEJM2013atwww.nejm.orgMDCOClinical+DataOperationsLEADERSHIPJennaBisch(ProjectLead)TracySurvill(DataLead)TiepuLi

u(Statistician)SteveElkin(Programming)MarkusDietrich(Medical)PROJECTMANAGEMENTDeniseEvansTaraRichardsonNitaWhyteIN-HOUSEOPERATIONSDanie

lBoisvertKathieVolcyLaurenEnsleyMariluMontalvoDATAMANAGEMENTCindyCleggKalpanaPullakhandamMichelleArthurGretchenCleggPamHoffmanKathleenTencerJuliaBa

ughSowersLucyWangunyuLindaConnollyCindyLazosSITEMANAGEMENTCOLsPeterDjuricCynthiaShadeMohammadArifLindaTilb

ergKateyFoxCRAsChristinaGerhardtScottStephensLetiVillafrancaKareyCropperLindaWillitsValMorrowCHAMPIONPHOENIXAROsandCROsP

artnersRoleAlmacIVRS/IWRSMergeeCRFQuestCKMBcentrallabBioclinicaWebportalforangiographicfilmuploadsCardiovascularResearchFounda

tionAngiographicCoreLabDukeClinicalResearchInstituteCECGreenLaneCoordinatingCenterSiteManagement–NewZea

landWorldwideClinicalTrialsSiteManagement–ROWexcl.US+NZMDCOSiteManagement-USPatientDispositionEnrolledpatientsw

ithStableAngina/NSTE-ACS/STEMIIndicatedforPCI(N=11,145)1:1RandomizationITTCANGRELOR(N=5581)ITTCLOPIDOGREL(N=5564)NoPCI(N=91)DidNotReceiveStu

dyDrug(N=52)NoPCI/NoStudyDrug(N=109)NoPCI(N=83)DidNotReceiveStudyDrug(N=37)NoPCI/NoStudyDrug(N=94)MITTCAN

GRELOR(N=5472)MITTCLOPIDOGREL(N=5470)Losttofollow-up(N=2)WithdrewConsent(N=1)48hourfollow-up(N=5470)48hourfollow-up(N=5469)Losttofollow-up(N=8)L

osttofollow-up(N=9)30dayfollow-up(N=5462)30dayfollow-up(N=5457)PCIPCIPrimaryEfficacyOutcomeat48Hours,MITTCangrelor(N=5472)Clopidogrel(N=5470)OR(95%

CI)P-valuePrimaryAnalysisAdjusted1Death/MI/IDR/ST257/5470(4.7%)322/5469(5.9%)0.78(0.66,0.93)0.005Clopi

dogrelLoading300mg81/1405(5.8%)95/1401(6.8%)0.84(0.62,1.14)0.27600mg176/4065(4.3%)227/4068(5.6%)0.77(0.

63,0.94)0.0091.Thelogisticmodelwasadjustedforbaselinestatusandclopidogreldose.BhattDL,StoneGW,MahaffeyKW,etal….Harrin

gtonRA.NEJM2013atwww.nejm.orgEfficacyOutcomesat48Hours,ITTCangrelor(N=5581)Clopidogrel(N=5564)OR(95%CI)PValueDeath/MI/IDR/ST(primary

endpoint,adjusted)260/5573(4.7%)325/5561(5.8%)0.79(0.67,0.93)0.005Stentthrombosis(keysecondaryendpoint)4

6/5573(0.8%)74/5561(1.3%)0.62(0.43,0.89)0.01MI207/5573(3.7)255/5561(4.6)0.80(0.67,0.97)0.02Q-waveMI11/5573(0.2)18/5561(0.3

)0.61(0.29,1.29)0.19IDR29/5573(0.5)38/5561(0.7)0.76(0.47,1.23)0.27Death20/5573(0.4)21/5561(0.4)0.95(0.51,1.75)0.87C

VDeath20/5573(0.4)21/5561(0.4)0.95(0.51,1.75)0.87BhattDL,StoneGW,MahaffeyKW,etal….HarringtonRA.NEJM2

013atwww.nejm.org